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Abstract
Introduction: Antihypertensive drugs lower the maternal blood pressure in pre-eclampsia (PE) by direct or central
vasodilatory mechanisms but little is known about the direct effects of these drugs on placental functions.
Objective: The aim of our study is to evaluate the effect of labetolol, hydralazine, a-methyldopa and pravastatin on the
synthesis of placental hormonal and angiogenic proteins know to be altered in PE.
Design: Placental villous explants from late onset PE (n = 3) and normotensive controls (n = 6) were cultured for 3 days at 10
and 20% oxygen (O2) with variable doses anti-hypertensive drugs. The levels of activin A, inhibin A, human Chorionic
Gonadotrophin (hCG), soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) were measured in explant
culture media on day 1, 2 and 3 using standard immunoassays. Data at day 1 and day 3 were compared.
Results: Spontaneous secretion of sEndoglin and sFlt-1 were higher (p,0.05) in villous explants from PE pregnancies
compared to controls. There was a significant time dependant decrease in the secretion of sFlt-1 and sEndoglin in PE cases,
which was seen only for sFlt-1 in controls. In both PE cases and controls the placental protein secretions were not affected
by varying doses of anti-hypertensive drugs or the different O2 concentration cultures, except for Activin, A which was
significantly (p,0.05) higher in controls at 10% O2.
Interpretation: Our findings suggest that the changes previously observed in maternal serum hormones and angiogenic
proteins level after anti-hypertensive treatment in PE could be due to a systemic effect of the drugs on maternal blood
pressure and circulation rather than a direct effect of these drugs on placental biosynthesis and/or secretion.
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Introduction
Normal placentation in human pregnancy is characterized by
deep invasion of the placental bed by the extravillous trophoblast
through the decidua down to the inner or junctional zone of the
uterine myometrium [1]. Placental-related diseases of pregnancy
are almost unique to the human species and affect around a third
of human pregnancies [2]. These diseases include mainly
miscarriages and pre-eclampsia (PE), which are respectively at
the opposite end of a spectrum of major disorders of the
development of the utero-placental interface. In miscarriage,
placentation is severely impaired from an early stage leading to
complete degeneration and rapid collapse of the placental
structure before the end of the first trimester [2]. In PE,
placentation is sufficient to allow partial development of the
placenta but too shallow for complete development of the utero-
placental circulation and normal fetal growth during the second
half of pregnancy [3,4].
The incomplete conversion of the end branches of the uterine
circulation in PE results in retention of smooth muscle cells within
their walls [5,6]. As a consequence, some vaso-reactivity persists in
the utero-placental vascular bed leading not only to reduced
perfusion of the intervillous chamber of the definitive placenta but
also to intermittent perfusion exposing the placental tissue to low
grade ischemia-reperfusion and chronic oxidative stress [7,8].
Chronic oxidative stress inside the placenta leads to progressive
damage of the villous tissue, fetal growth restriction and finally to
diffuse maternal endothelial cell dysfunction and clinical PE
[2,6,9,10].
The exact pathogenic molecular mechanisms leading to the
systemic endothelial dysfunction of PE remain to be determined
[11]. The endothelial dysfunction associated with PE involves
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multiple maternal organ systems including the placental tissue
itself resulting in major functional changes and progressive
‘‘placental insufficiency’’ [12]. Intra-placental oxygen (O2) distri-
bution is likely to be an important regulator of trophoblast
function in PE [6,10] but other factors such as immune
maladaption, excessive shedding of trophoblast debris, oxidative
stress and genetic factors have been found to contribute to the
pathogenesis of the abnormal placentation [2,11,13]. Production
of placental anti-angiogenic factors and in particular, soluble fms-
like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), have
been shown to be up-regulated in PE and their levels are found to
be increased in maternal circulation, weeks before the onset of the
disease [14,15]. Placental anti-angiogenic factors are released into
the maternal circulation and are known to disrupt the maternal
endothelium functions resulting in hypertension, proteinuria and
the other systemic manifestations of PE [11,12].
Anti-platelet agents, alpha- and beta-blockers, calcium channel
blockers, diuretics vasodilators (NO agents) and magnesium
sulphate are the main drugs used in the management of PE
[11]. Recent research using animal models to evaluate the
different secondary effects of the disease has revealed some of
the underlying mechanisms of PE [4]. However, PE is a disorder
of deep invasive placentation, limiting the study of pharmacologic
interventions to humans and a few other higher primates. We have
previously shown the anti-hypertensive drug a-methyldopa
(Mdopa) has an effect on maternal serum levels of angiogenic
proteins and placental hormones in pregnancies complicated by
PE [16,17]. This effect may be independent of Mdopa known
antihypertensive central action and we have suggested that Mdopa
may directly influence trophoblastic protein synthesis and/or
release and thus some of the main placental biological functions.
The aim of this study was to further investigate the possible effect
of Mdopa and the other drugs, routinely used in the management
and prevention of PE, on the placental secretion of hormones and
angiogenic protein known to be altered in pregnancies complicat-
ed by PE.
Materials and Methods
Women booked for elective delivery by caesarean section at
term at University College London Hospital (UCLH) were
recruited for this study. Women with a multiple pregnancy, with
a history of smoking, assisted reproductive treatment or with any
pre-existing medical disorders such as chronic hypertension,
diabetes, renal disease or immune disorders were excluded from
the study.
In the PE group (n = 3), the diagnosis of late onset PE was
confirmed using clinical and biochemical parameters [18]. The
maternal blood pressure (BP) was measured in duplicate using a
standard mercury sphygmomanometer and the average of two
readings taken. Korotkoff sounds 1 and 5 were used to define
systolic and diastolic BP respectively. The mean BP was calculated
as diastolic BP+1/3 pulse pressure. PE was defined according to
the guidelines of the International Society for the Study of
Hypertension in Pregnancy [19]. The diagnosis of PE was based
on two recordings of diastolic blood pressure 90 mm Hg, at least
four hours apart; or one recording of diastolic BP$120 mm Hg, in
a previously normotensive woman; and urine protein excretion $
300 mg in 24 hours, or two readings of ++ or more on dipstick
analysis of a midstream or catheter specimen of urine, if no 24
hour collection was available. In all 3 cases, the average resistance
and pulsatility indices were above the 95th centile of the normal
ranges.
The control group (n = 6) included only uncomplicated single-
ton spontaneous conceptions booked for elective caesarean section
at term. The indication for caesarean section in the controls was a
previous caesarean section in five cases and a fibroid in lower
segment with fetal transverse presentation in one case.
The study was approved by the Joint UCL/UCLH Committees
on the Ethics of Human Research (Reference Number: 05/
Q0505/82). All women received information about the study and
written consent was obtained prior to the caesarean section.
Samples
In both groups the placenta was collected immediately from the
operating theatre during a caesarean section. The placenta was
kept on a sterile tray and sterile forceps and scissors were used to
obtain five placental samples from central part. The samples were
then rinsed thoroughly between 5 to 7 times with sterile HBSS
(Hanks balanced salt solution, GIBCO, UK) to remove all blood
and blood clots. The villous samples were immediately transferred
to the laboratory, placed under the laminar flow hood and cut into
smaller placental biopsies of maximum 1 cm in diameter. Each
villous biopsy was weighed in a sterile Bijou bottle (Sterilin Ltd,
Staffordshire, UK) before transfer to the culture well containing
the medium.
In vitro cultures
Villous samples were cultured in sterile 12 well culture plates
(Nunc-immunoplate, SIGMA-Aldrich Co, UK). The culture
media contained Dulbecco’s modified eagle medium (DMEM,
GIBCO, UK) with glutamate and 10% fetal calf serum (SIGMA-
Aldrich Co, UK); 100 U/ml penicillin and 100 mg/ml strepto-
mycin. Each culture well-contained 1.5 ml of culture media and
were cultured in a humidified 5% CO2 incubator at 37uC, for 3
days.
We tested the following drugs at 3 different dosages as
previously described by Xu et al., [20,21]: labetolol (LABE) (low
dose 15.6 mgm/ml; medium dose 250 mg/ml; high dose 4000 mg/
ml), hydralazine (HDZ) (low dose 5 mg/ml; medium dose 125 mg/
ml; high dose 1000 mg/ml;), Mdopa (low dose 39 mg/ml; medium
dose 625 mg/ml; high dose 10000 mg/ml) and pravastatin sodium
(low dose 0.039 mg/ml; medium dose 1.25 mg/ml; high dose
20 mg/ml). Control medium included 75 ml of HBSS (GIBCO,
UK) for LABE, HDZ and pravastatin and 75 ml of 0.05 M of
HCL for Mdopa.
For each experiment, two sets of culture plates/drug from both
groups were incubated in 2 different CO2 incubators at ambient
atmospheric O2 concentration (20%) and 10% O2 concentration
as previously described [5].
After 24 hours of incubation (day 1), the culture supernatant
from all culture experiment was collected and frozen at 280 c
until assayed. The villous explants were washed three times with
HBSS (GIBCO, UK) and 1.5 ml of fresh culture medium and
75 ml of the different drug concentration solutions was added. The
same procedure was repeated on day 2 and day 3. For each
sample, after 24 h and 48 h, the media was removed and the
villous explants were washed and replaced with fresh culture
media and drug solutions.
All our experiments were carried out in triplicate wells and
minimum repeated 3 times totalling 540 samples analyzed for the
entire experiment.
Immunoassays
Total activin A (follistatin bound and unbound) was measured
using a two-site enzyme linked immunosorbent assays ELISA
[22,23]. Affinity purified human activin A was used as the assay
Anti-Hypertensive Drugs and Placental Synthesis
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standard. The detection limit of the assay for purified human
Activin A was 50 ng/ml. Intra- and inter assay coefficients of
variation were 9% and 10%, respectively.
Dimeric inhibin A was measured using a two-site ELISA
[25,26]. The sensitivity of the assay was 2 pg/ml and the intra-
and inter- assay variations were 5.2% and 6.5%, respectively.
hCG was measured using a commercially available kit from IBL
with standards at concentrations of 0 miu/ml, 5 miu/ml, 25 miu/
ml, 100 miu/ml, 200 miu/ml.
Human sFlt-1 and sEng were measured using a two-site
(ELISAs) from R & D Systems (Minneapolis, Minnesota, USA).
Measurements were conducted in duplicate according to the
manufacturer’s protocol. The assay was validated in our labora-
tory and dilution curves created to get the correct dilution for each
assay. The minimum detectable levels for sFlt-1, and sEng were
5 pg/ml and 7 pg/ml respectively. Intra- and inter-assay coeffi-
cients of variation respectively in our laboratory were as follows:
sFlt-1 7%, 9%; and sEng 6%, 8%, as previously described [17].
All measured concentrations were normalised against the gram
(g) weight of the tissue sample.
Statistical Analysis
The data were analyzed using the Pad Prism 5 statistical data
analysis and statistical software package (GraphPad Software, La
Jolla, CA, USA). Standard Kurtosis analysis indicated that some
values were not normally distributed and the results are presented
as median and standard deviation (SD). A non-parametric analysis
Mann-Whitney (Wilcoxon) W test was used to compared cases and
controls. A Kruskal-Wallis test with Dunns post hoc tests was
performed to evaluate statistical differences when more than 2
variables were tested. A P value of ,0.05 was considered
statistically significant.
Results
There was no significant difference in the median maternal age,
parity, body mass index (BMI) and gestation at delivery between
the PE and controls. The systolic and diastolic BP, levels of
proteinuria and of all hepatic enzymes were significantly (P,
0.001) higher in the PE compared to controls.
Baseline secretion
After 1 day in culture at ambient O2 (20%), the median levels of
sFlt-1 and sEng were significantly (P,0.05) higher in villous
explants from pregnancies presenting with PE than in normal
controls (figure 1). There was no difference in the levels of activin
A, inhibin A and hCG after 1 day in culture between the PE and
control group.
Effect of Time
There was a significant (P,0.001) decrease in all protein
median levels over the 3 days in culture at ambient O2 in both PE
samples and controls (figure 1). The most pronounced changes
were found in PE explants, which showed a 10-fold decrease for
Sflt1 and a 3-fold decrease for sEng, between day 1 and day 3 in
culture.
Effect of O2 concentrations
There was no difference in the placental hormones and
angiogenic protein secretion at different O2 concentrations, except
for the secretion of activin A which was significantly (P,0.05)
increased in the controls at 10% O2 during the first day in culture
and second day. This effect was not observed after 3 days in
culture.
Dose dependant effect of anti-hypertensive drugs
No significant difference was found in villous explants secretion
in both controls and PE cases when cultured for up to 3 days with
no drug (control media zero concentration) compared with
increasing doses of LABE (15.6, 250 and 4000 mg/ml), HDZ (5,
125 and 1000 mg/ml), Mdopa (39, 625 and 10,000 mg/ml) or
Pravastatin (0.039, 1.25 and 20 mg/ml) at ambient or 10% O2
concentration. Figures 1A and 1B illustrates the effect of no drug
compared with maximum dose for each drug tested after 1 day in
culture at ambient O2 on the median levels of placental hormones
and angiogenic protein.
Discussion
Our study shows that in vitro secretion of angiogenic proteins
sEng and sFlt-1 is higher in villous tissue obtained at the time of
elective caesarean section performed at term in women presenting
with late PE compared to normal controls obtained under the
same experimental condition. By contrast, in vitro secretion of
placental hormones inhibin A, activin A and hCG is not different
in PE than in controls although these proteins have been found in
higher concentrations in the circulation of women with PE,
months before they present with the clinical symptoms of the
disease. In both cases and controls, the secretion of all proteins
tested was time-dependent in vitro but not affected by the addition
of anti-hypertensive drugs or statins to the culture medium.
Tissue culture experiments have been previously used In PE to
evaluate the synthesis of various proteins and to test for the effect
of different O2 concentrations [24,25]. We found only two
previous studies on the effect of clonidine, diazoxide, frusemide
and hydralazine (HDZ) on placental production of sFlt-1, sEng
cytokines over 24 hours in placental explants from term
pregnancies complicated by PE [20,21]. With the exception of
frusemide, none of the other drugs tested in culture over 24 hours
had any effect on sFlt-1 and sEng production in placental explants
from both PE and normal controls. Furthermore, except for HDZ,
the other drugs studied are now rarely used in clinical practice for
the treatment of PE and other hypertensive disorders of pregnancy
[26,27]. Intravenous HDZ or LABE are both considered first-line
drugs for the management of acute and severe hypertension
during pregnancy whereas oral Mdopa or LABE are used most
commonly in the management of non-severe hypertension [27].
The pharmacokinetic, pharmacological effects and pharmaco-
genetic of these drugs are very different. HDZ acts by dilating
resistance arterioles, thus reducing peripheral resistance and has a
direct catecholamine-mediated positive inotropic and chronotrop-
ic stimulation of the heart, resulting in an increase in cardiac
output [28]. Mdopa is a DOPA analogue, which is converted to a
methyl-norepinephrine an agonist of presynaptic central nervous
system a2-adrenergic receptors [29]. Activation of these receptors
inhibits sympathetic nervous system output and lowers blood
pressure [30]. LABE is a b-blockers with antagonistic properties at
both a- and b-adrenergic receptors, with direct vasodilator activity
[31]. HDZ appears to activate guanylatecyclase, leading to
increase cyclic GMP in arterial vascular smooth muscle and
causing vasorelaxation [32]. The data of the present study indicate
that the anti-hypertensive drugs do not modify the trophoblastic
secretions of placental hormones and angiogenic proteins and up
to 3 days in culture suggesting that these drugs do not have a direct
effect on placental biosynthesis.
Clinical PE is associated with deficient intravascular production
of prostacyclin and excessive production of thromboxane, which is
a vasoconstrictor and stimulant of platelet aggregation. This
observation has led to the concept two decades ago that anti-
Anti-Hypertensive Drugs and Placental Synthesis
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platelet agents, mainly aspirin can be used from early in pregnancy
to prevent the development of PE [33]. 3-Hydroxy-3-methylglu-
taryl-coenzyme A (HMG-CoA) reductase is the key enzyme of
cholesterol synthesis and statins which are HMG-CoA reductase
inhibitors have been increasingly used in patients with hypercho-
lesterolemia and/or at risk of vascular diseases [34]. Pravastatin
and other statins have also been shown to reverse various
pathophysiologic pathways associated with PE, such as angiogenic
imbalance, endothelial injury, inflammation, and oxidative stress
[35]. Pravastatin has been shown to induce the VEGF-like
angiogenic factor placental growth factor (PGF) in a mouse model
but there are no data on its possible pharmacological effects on the
human placenta. The results of the present study indicate that
similarly to anti-hypertensive drugs, pravastatin does not have a
direct effect on placental biosynthesis of placental hormones and
angiogenic proteins.
Inhibin A, activin A and hCG are all produced by the villous
trophoblast and known to be increased in the second trimester
serum samples from women presenting with clinical PE later in
pregnancy [36]. There is mounting evidence that oxidative stress
or an imbalance in the oxidant/antioxidant activity in utero-
placental tissues plays a pivotal role in the development of PE [2].
Uterine contractions during labor are known to be associated with
intermittent utero-placental perfusion and placentas subjected to
prolonged active labor shown biological changes similar to those
observed in PE [37]. This is further demonstrated by the increase
in activin A and sFlt-1 maternal serum levels during labor
compared to pre-labor in PE [36]. We have previously shown that
the first trimester human placenta syncytiotrophoblast is acutely
sensitive to O2-mediated damage [38] and that the changes in
intra-placental O2 concentration during the first half of pregnancy
are essential for trophoblast differentiation and placental develop-
ment [39,40]. Furthermore, we recently found a direct relationship
in the early intrauterine PaO2 in vivo and inhibin A and sFLT-1
concentrations in placental bed blood confirming our hypothesis
by intrauterine O2 tension play a role in the placental proteins
synthesis [41]. It has also been recently suggested that the
oxidative status of the trophoblast may regulate glycosylation of
proteins and thereby modulate major trophoblast cell functions
[42]. In the present study, we found a significant increase in-vitro
of activin A synthesis during the first two days in culture at 10%
O2 in normal controls suggesting that intra-placental O2 tension
may have an effect on some placental synthesis during all three
trimesters in normal pregnancy. However, compared to the first
Figure 1. Comparison of the effect of no drug (0) compared with maximum (M) dose for LABE (4000 mg/ml), HDZ (1000 mg/ml),
Mdopa (10,000 mg/ml) and Pravastatin (20 mg/ml) after 1 day in culture at ambient O2 on the median (SD) levels of placental
hormones (Fig. 1A) and angiogenic protein (Fig. 1B). The beta errors for no drug versus max dose of Mdopa are: 0.0465 & 02451 on Inhibin A;
0.0001 & 0.9761 on Activin A; 0.0019 & 0.0367 for hCG; 0.0655 & 0.0054 for sFlt-1 and 0.0559 & 0.1977 for sEng, respectively.
doi:10.1371/journal.pone.0107644.g001
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trimester trophoblast, which develops in 8–10 O2 [2,5], the third
trimester villous tissue biological activities are less likely to affected
by changes in O2 tension in culture.
Activin A is know to promote the invasion of first-trimester
cytotrophoblast until 10 weeks gestation [43] may play a role in
the pathogenesis of PE by inducing excessive apoptosis in placenta
indirectly through enhancing Nodal expression [44,45]. It has
been recently suggested that the increase in placental secretion of
inhibin A, activin A and hCG results from premature accelerated
differentiation of the villous cytotrophoblasts and could be linked
to chronic intra-placental oxidative stress.
PE is almost exclusively a disorder of human deep placentation,
in-vitro cultures of human placental explants are essential to better
understand the pathophysiology of PE but also the impact of anti-
hypertensive drugs on placental biology. As shown in the present
study, the biosynthesis of these placental hormones does not seem
to be influenced by the presence of anti-hypertensive drugs or
Pravastatin in the culture medium. Our study is limited to late-
onset PE and included only three cases but we assume that the
samples represent the same process and are therefore justified in
repetitive sampling of three placenta specimens. The effects of
anti-hypertensive drugs are not restricted to the placenta but a
better understanding the impact of these drugs on placental
functions in PE is essential to the development of more selectively
targeted drugs ensuring swift introduction of optimal treatment
whilst minimizing the use of inappropriate or ineffective drugs.
Author Contributions
Conceived and designed the experiments: SG SM EJ. Performed the
experiments: SG. Analyzed the data: SG SM. Contributed reagents/
materials/analysis tools: SM EJ. Wrote the paper: SG SM EJ.
References
1. Pijnenborg R, Vercruysse L, Brosens I (2011) Deep placentation. Best Pract Res
Clin Obstet Gynaecol 25: 273–285.
2. Jauniaux E, Poston L, Burton GJ (2006) Placental-related diseases of pregnancy:
Involvement of oxidative stress and implications in human evolution. Hum
Reprod Update 12: 747–755.
3. Khong Y, Brosens I (2011) Defective deep placentation. Best Pract Res
ClinObstetGynaecol. 25: 301–311.
4. Brosens I, Pijnenborg R, Vercruysse L, Romero R (2011) The ‘‘Great
Obstetrical Syndromes’’ are associated with disorders of deep placentation.
Am J Obstet Gynecol. 204: 193–201.
5. Burton GJ, Charnock-Jones DS, Jauniaux E (2006) Working with oxygen and
oxidative stress in vitro. Methods Mol Med 122: 413–25.
6. Kimura C, Watanabe K, Iwasaki A, Mori T, Matsushita H, et al. (2012) The
severity of hypoxic changes and oxidative DNA damage in the placenta of early-
onset preeclamptic women and fetal growth restriction. J Matern Fetal Neonatal
Med 26: 491–496.
7. Hung TH, Skepper JN, Burton GJ (2001) In vitro ischemia-reperfusion injury in
term human placenta as a model for oxidative stress in pathological pregnancies.
Am J Pathol 159: 1031–1043.
8. Hung T, Charnock-Jones D, Skepper J, Burton G (2004) Secretion of tumour
necrosis factor alpha from human placental tissues induced by hypoxia-
reoxygenation causes endothelial cell activation in vitro: a potential mediator of
inflammatory response in pre-eclampsia. Am J Pathol 164: 1049–1061.
9. Vanderlie J, Venardos K, Clifton VL, Gude NM, Clarke FM, et al. (2005)
Increased biological oxidation and reduced anti-oxidant enzyme activity in pre-
eclamptic placentae. Placenta 26: 53–58.
10. Lee SM, Romero R, Lee YJ, Park IS, Park CW, et al. (2012) Systemic
inflammatory stimulation by microparticles derived from hypoxic trophoblast as
a model for inflammatory response in preeclampsia. Am J Obstet Gynecol 207:
337. e1–8.
11. Williams PJ, Morgan L (2012) The role of genetics in pre-eclampsia and
potential pharmacogenomic interventions. Pharmgenomics Pers Med 5: 37–51.
12. Vatten LJ, Asvold BO, Eskild A (2012) Angiogenic factors in maternal
circulation and preeclampsia with or without fetal growth restriction. Acta
Obstet Gynecol Scand 91: 1388–1394.
13. Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, et al.
(2012) Review: Does size matter? Placental debris and the pathophysiology of
pre-eclampsia. Placenta 33: S48–54.
14. Anderson UD, Olsson MG, Kristensen KH, A˚kerstro¨m B, Hansson SR (2012)
Biochemical markers to predict preeclampsia. Placenta 33: S42–47.
15. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post
JA, et al. (2012) Accuracy of circulating placental growth factor, vascular
endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin
in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG
119: 778–787.
16. Khalil A, Muttukrishna S, Harrington K, Jauniaux E (2008) Effect of
Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic
Factors in Pregnancies with Hypertensive Disorders. PLoS ONE 3: e2766.
17. Khalil A, Jauniaux E, Harrington K, Muttukrishna S (2009) Placental
production and maternal serum and urine levels of inhibin A and activin A
are modified by antihypertensive therapy in hypertensive disorders of
pregnancy. Clin Endocrinol 70: 924–391.
18. Kucukgoz Gulec U, Ozgunen FT, Buyukkurt S, Guzel AB, Urunsak IF, et al.
(2013) Comparison of Clinical and Laboratory Findings in Early- and Late-
Onset Preeclampsia. J Matern Fetal Neonatal Med 26: 1228–1233.
19. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM (2001)
The classification and diagnosis of the hypertensive disorders of pregnancy:
statement from the International Society for the Study of Hypertension in
Pregnancy (ISSHP) Hypertens Pregnancy 20: IX–XIV.
20. Xu B, Makris A, Thornton C, Ogle R, Horvath JS, et al. (2006)
Antihypertensive drugs clonidine, diazpxide, hydralazine and furosemide
regulate the production of cytokines by placenta and peripheral blood
mononuclear cells in normal pregnancy. J Hypertension 24: 915–922.
21. Xu B, Thornton C, Tooher J, Ogle R, Lim S, et al. (2009) Effects of anti-
hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and
soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin
Exp Pharmacol Physiol 36: 839–842.
22. Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG (1996) Changes
in peripheral serum levels of total activin A during the human menstrual cycle
and pregnancy. J Clin Endocrinol Metab 81: 3328–3334.
23. Muttukrishna S, Jauniaux E, McGarrigle H, Groome N, Rodeck CH (2004) In-
vivo concentrations of inhibins, activin A and follistatin in human early
pregnancy. Reprod Biomed Online 8: 712–719.
24. Royle C, Lim S, Xu B, Tooher J, Ogle R, et al. (2009) Effect of hypoxia and
exogenous IL-10 on the pro-inflammatory cytokine TNF-alpha and the anti-
angiogenic molecule soluble Flt-1 in placental villous explants. Cytokine 47: 56–
60.
25. Orendi K, Kivity V, Sammar M, Grimpel Y, Gonen R, et al. (2011) Placental
and trophoblastic in vitro models to study preventive and therapeutic agents for
preeclampsia. Placenta 32: S49–54.
26. Vest AR, Cho LS (2012) Hypertension in pregnancy. Cardiol Clin 30: 407–423.
27. Kattah AG, Garovic VD (2013) The management of hypertension in pregnancy.
Adv Chronic Kidney Dis 20: 229–239.
28. Cohn JN, McInnes GT, Shepherd AM (2011) Direct-acting vasodilators. J Clin
Hypertens13: 690–692.
29. Head GA, Chan CK, Burke SL (1998) Relationship between imidazoline and
alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally
acting antihypertensive agents. J Auton Nerv Syst 72: 163–169.
30. Head GA (1999) Central imidazoline- and alpha 2-receptors involved in the
cardiovascular actions of centrally acting antihypertensive agents. Ann N Y A-
cad Sci 881: 279–286.
31. Falkay G, Melis K, Kovacs L (1994) Correlation between beta- and alpha-
adrenergic receptor concentrations in human placenta. J Recept Res 14: 187–
195.
32. Leitch IM, Read MA, Boura AL, Walters WA (1994) Effect of inhibition of nitric
oxide synthase and guanylatecyclase on hydralazine-induced vasodilatation of
the human fetal placental circulation. Clin Exp Pharmacol Physiol 2: 615–622.
33. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, et al. (1993)
Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous
pregnant women. The National Institute of Child Health and Human
Development Network of Maternal-Fetal Medicine Units. N Engl J Med 329:
1213–1218.
34. Duggan ST (2012) Pitavastatin: a review of its use in the management of
hypercholesterolaemia or mixed dyslipidaemia. Drugs 72: 565–584.
35. Costantine MM, Cleary K (2013) Eunice Kennedy Shriver National Institute of
Child Health and Human Development Obstetric-Fetal Pharmacology Re-
search Units Network. Pravastatin for the prevention of preeclampsia in high-
risk pregnant women. Obstet Gynecol 121: 349–353.
36. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S (2009) Maternal
circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in
normal pregnancy and pre-eclampsia. PLoS One 4:e4453.
37. Cindrova-Davies T, Yung HW, Johns J, Spasic-Boskovic O, Korolchuk S, et al.
(2007) Oxidative stress, gene expression, and protein changes induced in the
human placenta during labor. Am J Pathol 171: 1168–1179.
38. Watson AL, Skepper JN, Jauniaux E, Burton GJ (1998) Susceptibility of human
placental syncytiotrophoblastic mitochondria to oxygen-mediated damage in
relation to gestational age. J Clin Endocrinol Metab 83: 1697–1705.
Anti-Hypertensive Drugs and Placental Synthesis
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e107644
39. Jauniaux E, Watson AL, Hempstock J, Bao YP, Skepper JN, et al. (2000) Onset
of maternal arterial blood flow and placental oxidative stress. A possible factor in
human early pregnancy failure. Am J Pathol 2000; 157: 2111–2122.
40. Jauniaux E, Hempstock J, Greenwold N, Burton GJ (2003) Trophoblastic
oxidative stress in relation to temporal and regional differences in maternal
placental blood flow in normal and abnormal early pregnancies. Am J Pathol
162: 115–125.
41. Muttukrishna S, Suri S, Groome N, Jauniaux E (2008) Relationships between
TGF-beta proteins and oxygen concentrations inside the first trimester human
gestational sac. PLoS One 3:e2302.
42. Pidoux G, Gerbaud P, Cocquebert M, Segond N, Badet J, et al. (2012) Human
trophoblast fusion and differentiation: lessons from trisomy 21 placenta. Placenta
33: S81–86.
43. Bearfield C, Jauniaux E, Groome N, Sargent IL, Muttukrishna S (2005) The
secretion and effect of inhibin A, activin A and follistatin on first-trimester
trophoblasts in vitro. Eur J Endocrinol 152: 909–916.
44. Nadeem L, Munir S, Fu G, Dunk C, Baczyk D, et al. (2011) Nodal signals
through activin receptor-like kinase 7 to inhibit trophoblast migration and
invasion: implication in the pathogenesis of preeclampsia. Am J Pathol 178:
1177–89.
45. Yu L, Li D, Liao QP, Yang HX, Cao B, et al. (2012) High levels of activin a
detected in preeclamptic placenta induce trophoblast cell apoptosis by
promoting nodal signalling. J Clin Endocrinol Metab 97: 1370–1379.
Anti-Hypertensive Drugs and Placental Synthesis
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e107644
